Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Anti-HIV Drugs may Protect Against Puberty Delays in HIV-Infected Children

Published: Thursday, August 15, 2013
Last Updated: Thursday, August 15, 2013
Bookmark and Share
NIH-funded study shows children on newer regimens closer to normal timetable.

For children who have been HIV-infected since birth, current anti-HIV drug regimens may protect against the delays in puberty that had been seen in HIV-infected children taking older regimens, according to researchers funded by the National Institutes of Health.

HIV appears to delay puberty. Among children born before 1990, more than 10 percent of HIV-positive girls and boys had not entered puberty by 12 and 13 years of age, respectively. However, a study published in the journal AIDS has found that puberty was delayed for less than 1 percent of children born since 1997, when more effective anti-HIV drug therapies became widely available. Combination antiretroviral treatments — three or more drugs from two or more different anti-HIV drug classes — are now the standard therapy.

Presumably, improved health resulting from the more effective therapy allows the children to enter puberty on a more age appropriate timetable, said study author Rohan Hazra, M.D., of the Maternal and Pediatric Infectious Disease Branch of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).

Based on information collected over 12 years from more than 2,000 HIV-infected boys and girls, the researchers found that for each year of combination antiretroviral treatment a child received, puberty started about a month earlier when compared to children with HIV who took other drug therapies or no drugs at all.

“More than 80 percent of the children in the study born after 1997 are on a combination regimen, so it was difficult to make a comparison between those who received the therapy and the comparatively small number who did not,” said the study’s first author, Paige Williams, Ph.D., of the Harvard School of Public Health, Boston. “However, the trend in the data suggests that children taking modern drug regimens are likely to experience puberty closer in time to that of their HIV-negative peers.”

The study also included researchers at the University of Colorado School of Medicine and Children’s Hospital Colorado, Aurora; Tulane University School of Medicine, New Orleans; Indiana University School of Medicine, Indianapolis; New York University School of Medicine; New Jersey Medical School, Newark; and Children’s Hospital Los Angeles.

Data for the study were obtained from three NICHD-supported HIV research networks: The International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Network, the Pediatric AIDS Clinical Trials Group (a predecessor of the IMPAACT Network) and the Pediatric HIV/AIDS Cohort Study.

Major funding for this study came from NICHD and the National Institute of Allergy and Infectious Diseases, also part of NIH. Additional support came from six other NIH institutes: the National Institute of Mental Health, the National Institute on Deafness and Other Communication Disorders, the National Heart, Lung, and Blood Institute, the National Institute of Neurological Disorders and Stroke and the National Institute on Alcohol Abuse and Alcoholism.

To conduct their study, the researchers analyzed data from more than 2,000 boys and girls with HIV and from an additional 500 boys and girls exposed to HIV before and during birth but who did not become HIV infected. The researchers analyzed data obtained on these boys and girls starting from age 7. During the children’s study visit, clinicians assessed the beginning of puberty by noting typical physical changes that occur in adolescence, such as the appearance of pubic hair and the development of breast tissue or genitals.

Researchers confirmed previous findings indicating that HIV can delay the start of puberty. HIV-positive boys started developing pubic hair and larger genitals when they were about 11.5 years old, on average — about a year later than their HIV-negative peers. HIV-positive girls started developing breasts and pubic hair when they were 10.5 years old, compared to 9.5 to 10 years old, on average, for HIV-negative girls. For their analysis, the researchers took into account the trend in recent years toward earlier puberty in U.S. children, as well as racial and ethnic differences in the timing of puberty. However, even after adjusting for these factors, the researchers found that puberty began four to six months later in HIV-positive boys and girls than in children who did not have HIV.

“In studies of the general population, maturing later has been linked to lower self-esteem and depression, and delays also raise concerns about a person’s future reproductive health,” Dr. Hazra said. “So differences of four to six months may have significant effects.”

The researchers also confirmed that the youth with the most severe symptoms of HIV infection tended to have the greatest delays in puberty.

“As combination regimens for treating HIV have become more widespread, children’s growth has improved and their physical maturation is much closer to the norm,” Dr. Williams added. “Today’s recommended treatments for HIV appear to have a protective effect in these regards.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Study to Assess Shorter-Duration Antibiotics in Children
Physicians plan a clinical trial to evaluate whether short course anti-biotics are effective at treating CAP in children.
Wednesday, November 30, 2016
First New HIV Vaccine Study for Seven Years Begins
South Africa hosts historic clinical trial of experimental HIV vaccine aiming to safely prevent HIV infection.
Wednesday, November 30, 2016
Testing Zika Vaccine in Humans Begins
The first of five planned clinical trials to test ZPIV vaccine in humans has begun.
Tuesday, November 08, 2016
Skin Patch to Treat Peanut Allergy
NIH-funded study suggests peanut protein patch is a safe and convenient method of treatment.
Thursday, October 27, 2016
NIH Contributes to Global Effort to Prevent and Manage Lung Diseases
The large scale trial will measure health benefits of clean cookstoves.
Thursday, October 20, 2016
Scientists at NIH and Emory Achieve Sustained SIV Remission in Monkeys
The finding suggest that the immune systems of these animals are controlling SIV replication in the absence of antiretroviral therapy.
Friday, October 14, 2016
Drug to Treat Alcohol Use Disorder Shows Promise Among Drinkers With High Stress
The findings suggest that potential future studies with drugs targeting vasopressin blockade should focus on populations of people with AUD who also report high levels of stress.
Friday, September 30, 2016
Stem Cell Therapy Heals Injured Mouse Brain
A team of researchers has developed a therapeutic technique that dramatically increases the production of nerve cells in mice with stroke-induced brain damage.
Tuesday, August 23, 2016
Zika Vaccine Testing in Humans
The NAAID has initiated a clinical trail of a vaccine candidate for the prevention of the Zika virus infection.
Thursday, August 04, 2016
NIH Begins Yellow Fever Vaccine Trial
NIH has initiated an early-stage clinical trial of a vaccine to protect against yellow fever.
Thursday, July 28, 2016
NIH-Funded Center to Study Inefficiencies in Clinical Trials
Researchers at the Duke Clinical Research Institute (DCRI) and Vanderbilt University Medical Center (VUMC) have received a major federal grant to study how multisite clinical trials of new drugs and therapies in children and adults can be conducted more rapidly and efficiently.
Thursday, July 07, 2016
PREVAIL Treatment Trial for Men with Persistent Ebola Viral RNA
The six-month study will enroll 60 to 120 EVD survivors.
Wednesday, July 06, 2016
Investigational Malaria Vaccine Protects Healthy U.S. Adults
Researchers at NIH have found that the malaria vaccine protected a small number of healthy, malaria-naïve adults in the U.S. from infection for more than one year after immunization.
Tuesday, May 10, 2016
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
Wednesday, April 20, 2016
Submissions Open for the Cancer Moonshot Program
NCI opens online platform to submit ideas about research for Cancer Moonshot.
Tuesday, April 19, 2016
Scientific News
Making It Personal
Cancer vaccine linked to increased immune response against leukemia cells.
Gene Therapy Maintains Clotting Factor for Hemophilia Patients
Following a single gene therapy dose, the highest levels of an essential blood clotting factor IX were observed in hemophilia B patients.
BioCision Forms MedCision
The new company will focus on technologies for the management and automation of vital clinical processes.
First New HIV Vaccine Study for Seven Years Begins
South Africa hosts historic clinical trial of experimental HIV vaccine aiming to safely prevent HIV infection.
Study to Assess Shorter-Duration Antibiotics in Children
Physicians plan a clinical trial to evaluate whether short course anti-biotics are effective at treating CAP in children.
Cancer Gene Predicts Treatment Response in Leukaemia
Study indicates the patients suffering from a lethal for of acute myeloid leukemia may live longer when receiving milder chemotherapy drugs.
Injectable Biologic Therapy Reduces Triglycerides
Study finds first-of-its-kind therapy promising for patients with high triglycerides, cholesterol.
Testing Zika Vaccine in Humans Begins
The first of five planned clinical trials to test ZPIV vaccine in humans has begun.
Combination Therapy Improved Chemoresistance in Ovarian Cancer
The study demonstrates how an existing class of targeted therapies could be used to potentiate the tumor suppression induced by cisplatin.
Gene Therapy for Blistering Skin Disease Shows Promise
Grafting genetically altered skin onto patients’ chronic wounds marks the first time skin-based gene therapy has been demonstrated to be safe and effective in humans.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!